Drugs Containing Excipient (Inactive Ingredient) POVIDONE-IODINE

Generic drugs containing POVIDONE-IODINE excipient

Company	Ingredient	NDC	Excipient
Cameron Pharmaceuticals	metaxalone	42494-449	POVIDONE-IODINE

Povidone-Iodine Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 22, 2026

Povidone-iodine is primarily an antiseptic active pharmaceutical ingredient, not a conventional excipient. The commercial product is a complex of iodine and povidone, also called polyvinylpyrrolidone or PVP. Its financial trajectory depends on three linked markets: pharmaceutical-grade povidone, iodine, and finished antiseptic formulations. Demand is stable rather than high-growth, with expansion concentrated in emerging markets, surgical antisepsis, wound care, veterinary products, and institutional infection control.

The market has limited public financial transparency. Suppliers generally report povidone, iodine, or specialty excipients within broader business segments rather than as separate product lines. As a result, company revenue exposure and market-size estimates require proxy analysis rather than reliance on a single published market figure.

What is povidone-iodine and how is it used in pharmaceutical products?

Povidone-iodine is a water-soluble complex that releases free iodine gradually. Povidone acts as the carrier and controls iodine availability, while iodine provides the antimicrobial effect.

Common pharmaceutical and healthcare formats include:

Product format	Typical use	Commercial significance
5% or 10% topical solution	Skin antisepsis and wound cleansing	Largest established use category
Surgical scrub	Preoperative hand and skin preparation	Institutional and hospital demand
Ointment	Minor wounds and localized antisepsis	Retail and hospital use
Gargle and mouthwash	Oral and throat antisepsis	Regional market, subject to local regulation
Ophthalmic preparation	Perioperative ocular antisepsis	Specialist, higher quality requirements
Vaginal or mucosal formulations	Local antiseptic use	Country-specific regulatory status
Veterinary solution	Animal wound care and surgery	Diversifies demand beyond human healthcare

A key technical distinction affects procurement. Finished povidone-iodine products normally require a defined active iodine content, viscosity, pH range, microbial profile, and release profile. Povidone used as a pharmaceutical excipient in tablets, capsules, and liquid formulations is a separate product category. It is not interchangeable with povidone-iodine.

How large is the povidone-iodine pharmaceutical market?

Published market estimates vary widely because analysts define the category differently. Some include only topical antiseptic products. Others include hospital infection-control products, wound care, veterinary products, oral products, and raw materials. There is no universally accepted reporting category for "povidone-iodine excipient."

The more defensible market structure is:

1. Pharmaceutical-grade povidone and PVP.
2. Iodine and iodine derivatives.
3. Povidone-iodine active complexes.
4. Finished antiseptic products.
5. Hospital and institutional procurement.

The finished-product market is larger than the raw-material market. Suppliers of pharmaceutical-grade povidone participate in a broader excipient market that includes binders, film formers, solubilizers, and suspension aids. Suppliers of povidone-iodine compete in a narrower antiseptic market with stronger formulation and regulatory requirements.

What drives demand for povidone-iodine?

Demand is supported by:

• Surgical procedures and hospital admissions.
• Preoperative skin preparation.
• Wound-care volume.
• Infection-prevention protocols.
• Retail antiseptic use.
• Veterinary medicine.
• Public-health purchasing during infection outbreaks.
• Expansion of healthcare infrastructure in Asia-Pacific, Latin America, and the Middle East.

Demand is constrained by:

• Competition from chlorhexidine, alcohol-based preparations, hydrogen peroxide, and octenidine.
• Iodine sensitivity and thyroid-related labeling considerations.
• Restrictions for some neonatal, ocular, thyroid, and mucosal uses.
• Product commoditization.
• Hospital purchasing pressure.
• Substitution by combination products and alcohol-based surgical preparations.

The market therefore has a defensive growth profile. Volume can rise with procedure growth, but pricing power remains limited outside specialized formulations.

Which companies supply povidone, iodine, and povidone-iodine products?

The supply chain is fragmented across raw materials, excipients, active complexes, and finished dosage forms.

Pharmaceutical-grade povidone suppliers

Important global excipient suppliers include:

• BASF, through Kollidon povidone and related pharmaceutical excipients.
• Ashland, through Plasdone povidone and related pharmaceutical polymers.
• JRS Pharma and other regional excipient manufacturers.
• Chinese and Indian producers supplying pharmaceutical-grade PVP and PVP-iodine.

These companies may supply povidone as a standalone excipient or as a component used to manufacture povidone-iodine. Their financial exposure is usually reported within pharmaceutical ingredients, life sciences, specialty ingredients, or performance materials.

Povidone-iodine and finished-product suppliers

The finished-product landscape includes:

• Betadine, historically associated with Purdue Pharma and international licensees.
• Mundipharma and regional marketing partners.
• Dynarex and other hospital and retail suppliers.
• Indian manufacturers such as Win-Medicare and other generic antiseptic producers.
• Japanese and Asian pharmaceutical companies serving local markets.
• Contract manufacturers producing private-label hospital and retail products.

Brand ownership, manufacturing, and distribution rights vary by country. A brand-level relationship in the United States does not establish ownership or distribution rights in Europe, India, Japan, or Latin America.

What is the financial trajectory for povidone-iodine?

The financial trajectory is best described as stable growth with periodic volume shocks rather than rapid structural expansion.

Historical trajectory

Before 2020, demand was linked mainly to surgery, wound care, retail antiseptics, and veterinary use. Pricing was generally competitive because multiple manufacturers supplied the product.

During the COVID-19 period, demand for antiseptic products increased sharply. Retail shortages, institutional stockpiling, logistics disruption, and higher iodine and packaging costs affected margins. That increase was temporary. As inventories normalized, demand shifted back toward procedure-linked consumption.

From 2022 onward, the market experienced four countervailing trends:

• Higher energy, labor, logistics, and packaging costs.
• Normalization of retail antiseptic demand.
• Recovery in elective procedures.
• Increased competition from alcohol and chlorhexidine products.

The result was a more moderate financial profile than the exceptional growth recorded during the pandemic.

Forward trajectory

The most likely base case through the late 2020s is low- to mid-single-digit annual value growth in finished povidone-iodine products, with volume growth generally lower than value growth when input costs rise. Specialty ophthalmic, wound-care, and hospital formulations should outperform basic solutions, while private-label topical products will remain price-sensitive.

Scenario	Demand pattern	Margin outlook	Main trigger
Base case	Low- to mid-single-digit value growth	Stable to modestly pressured	Procedure recovery and emerging-market expansion
Upside case	Above-market growth	Improved mix and utilization	Higher hospital adoption, export growth, supply disruption
Downside case	Flat or low growth	Margin compression	Substitution, procurement pricing, or raw-material inflation

No major supplier publicly isolates povidone-iodine revenue in a way that permits a reliable product-level earnings forecast. Financial analysis must therefore use segment revenue, capacity, pricing, and product-mix indicators.

What are the main cost and margin drivers?

The main cost drivers are iodine, povidone, solvents, packaging, quality control, energy, and regulatory compliance.

Iodine exposure

Iodine is a relatively concentrated input. Supply is geographically exposed to Chilean caliche deposits, Japanese production, and recycling or recovery streams. Changes in iodine availability can affect both cost and lead times.

Iodine price volatility is more consequential for povidone-iodine than for ordinary povidone excipients because iodine is a direct active component. A supplier with secured iodine procurement or integrated production has a structural advantage during tight markets.

Povidone exposure

Povidone cost depends on molecular-weight grade, residual monomer control, moisture, viscosity, manufacturing scale, and pharmaceutical quality systems. Pharmaceutical-grade material commands a premium over industrial PVP.

High-molecular-weight grades can create processing and dissolution challenges. Low-molecular-weight grades may provide different release and viscosity profiles. Formulators cannot always replace one grade without stability, performance, and regulatory work.

Packaging and filling

Povidone-iodine is sold in bottles, sachets, single-use applicators, wipes, and institutional containers. Packaging contributes materially to cost, particularly for sterile or unit-dose presentations. Plastic compatibility, light protection, closure integrity, and iodine adsorption must be evaluated.

What formulations are protected by intellectual property?

Povidone-iodine is a mature technology. The basic povidone-iodine complex is unlikely to provide a durable standalone exclusivity position in major markets. Commercial protection usually comes from formulation, delivery, manufacturing, branding, and regulatory execution.

Potentially protectable areas include:

• Controlled iodine-release systems.
• Low-irritancy formulations.
• Ophthalmic or mucosal delivery systems.
• Stable gels, foams, films, wipes, and dressings.
• Combinations with other antiseptic agents.
• Reduced-staining or reduced-odor formulations.
• Packaging that limits iodine loss.
• Manufacturing methods that improve iodine availability or stability.
• Specific concentration, pH, viscosity, or excipient combinations.

The strongest commercial barriers are often regulatory and manufacturing barriers rather than broad composition patents.

How strong is the patent estate for povidone-iodine?

The estate is generally weak for the basic antiseptic concept and stronger for narrow delivery systems. Older foundational patents would ordinarily be expired or commercially irrelevant. Current protection, where available, is more likely to cover a specific dosage form or combination.

Patent strength should be assessed using:

• Claim breadth.
• Remaining term.
• Enablement across concentration ranges.
• Freedom to operate around alternative iodine carriers.
• Clinical or regulatory dependence on the claimed formulation.
• Manufacturing complexity.
• Availability of non-infringing substitutes.

A patent covering a specific iodine-release dressing may have commercial value even when ordinary povidone-iodine solution is effectively commoditized.

What is the FDA regulatory and Orange Book status of povidone-iodine?

In the United States, povidone-iodine topical products have historically been regulated under the FDA topical antiseptic framework, including the over-the-counter antiseptic drug monograph pathway. The FDA's tentative and final monograph activities for topical antiseptics have changed over time, and product status depends on formulation, labeling, concentration, and intended use. Sponsors must evaluate the applicable current monograph and FDA requirements before commercializing a product. [1]

Povidone-iodine as a raw material or excipient does not have an independent Orange Book listing. The FDA Orange Book principally identifies approved prescription drug products and associated patents or exclusivity. A conventional over-the-counter povidone-iodine antiseptic is not ordinarily analyzed as an Orange Book-listed reference product in the same manner as a prescription tablet or injectable. [2]

Are Paragraph IV challenges relevant?

Paragraph IV litigation is generally not the central risk for conventional povidone-iodine antiseptics. A generic drug applicant could use an abbreviated pathway only where the product and regulatory route qualify. Most commercial disputes are more likely to involve:

• Trademark and trade-dress issues.
• Labeling and advertising.
• Formulation patents.
• Manufacturing know-how.
• Procurement contracts.
• Product liability.
• Regulatory compliance.

When does povidone-iodine lose exclusivity?

The basic povidone-iodine technology has no single future loss-of-exclusivity date comparable to a branded prescription medicine. The core product is mature, and competition already exists across multiple manufacturers and countries.

Exclusivity may still apply to a particular:

• Brand.
• Dosage form.
• Device.
• Combination product.
• Manufacturing process.
• Regulatory approval.
• Market-specific license.

For those products, the relevant dates are patent expiration, regulatory exclusivity expiration, trademark status, and contract termination. A broad market entry date cannot be assigned to povidone-iodine as a category.

What litigation and settlement issues affect the market?

Povidone-iodine has a lower litigation profile than innovative prescription medicines. The main legal risks are product-specific.

Typical disputes

• Patent claims for wound dressings, films, gels, or controlled-release systems.
• Trademark disputes involving "Betadine" or similar brand names.
• Product liability claims concerning burns, ocular exposure, thyroid effects, or improper use.
• Regulatory actions over antiseptic claims.
• Contract disputes between brand owners, licensees, and manufacturers.
• Supply agreements involving iodine or pharmaceutical-grade povidone.

There is no widely recognized market-wide settlement agreement that determines generic entry for ordinary povidone-iodine solution. Licensing arrangements are usually territorial and brand-specific.

How does povidone-iodine compare with competing antiseptics?

Attribute	Povidone-iodine	Chlorhexidine	Alcohol-based products	Hydrogen peroxide
Primary strength	Broad antimicrobial activity	Persistent activity and surgical use	Rapid action	Oxidizing antisepsis
Formulation flexibility	High	Moderate	High but flammable	Moderate
Cost position	Competitive	Often higher in specialty products	Low to moderate	Low
Key limitation	Iodine-related restrictions and staining	Compatibility and safety concerns	Short residual activity and flammability	Tissue-irritation and limited use cases
Patent intensity	Low for basic products	Higher for specialized combinations	Low to moderate	Low
Procurement risk	Input sensitivity to iodine	Formulation and active-ingredient supply	Alcohol supply and storage	Commodity pricing

Chlorhexidine is the most important hospital competitor in surgical antisepsis. Alcohol-based products compete strongly in hand hygiene and rapid skin preparation. Povidone-iodine retains advantages in broad-spectrum use, formulation familiarity, and availability across retail and institutional channels.

What generic entry risks exist for povidone-iodine products?

Generic entry risk is high for standard solutions, scrubs, ointments, and low-complexity products. Entry barriers increase for:

• Sterile ophthalmic formulations.
• Unit-dose devices.
• Advanced wound dressings.
• Controlled-release systems.
• Products with proprietary applicators.
• Formulations supported by clinical data.
• Products requiring specialized stability packages.

Manufacturing barriers include iodine handling, validated complex formation, control of free iodine, microbial control, packaging compatibility, and batch-to-batch consistency. These barriers can protect margins even when patent protection is limited.

What is the geographic coverage of the market?

Asia-Pacific is the most important expansion region because of population, procedure growth, pharmaceutical manufacturing capacity, and hospital infrastructure investment. India and China have large domestic manufacturing bases and export capabilities.

North America and Europe are mature markets with higher regulatory and quality requirements. Growth is more dependent on specialty formulations, hospital purchasing, wound care, and product replacement than on basic antiseptic volume.

Latin America, the Middle East, and Africa offer expansion potential through retail antiseptics, hospital procurement, and local manufacturing. Currency volatility, import controls, tender pricing, and distributor dependence can reduce realized margins.

What are the revenue exposure and investment implications?

Povidone-iodine is unlikely to be a major standalone revenue driver for diversified chemical or pharmaceutical companies. Its value is greater as part of a portfolio that includes:

• Pharmaceutical-grade excipients.
• Contract manufacturing.
• Wound-care products.
• Hospital antiseptics.
• Ophthalmic products.
• Veterinary medicines.
• Specialty packaging and delivery systems.

The strongest financial positions are likely to belong to suppliers with secured iodine access, regulatory-grade manufacturing, multiple geographic approvals, and differentiated delivery formats. Commodity solution manufacturers remain exposed to price competition and hospital tender pressure.

Key Takeaways

• Povidone-iodine is primarily an antiseptic active ingredient, not a conventional excipient.
• The market has stable demand, but product-level financial disclosure is limited.
• Basic solutions and scrubs face high generic and private-label competition.
• Specialty ophthalmic, wound-care, device-based, and controlled-release products have better margin potential.
• Iodine supply, pharmaceutical-grade povidone, packaging, and quality systems drive cost.
• The basic technology has limited current patent leverage; formulation and delivery patents provide the principal IP opportunities.
• Povidone-iodine has no single category-wide patent expiration or Orange Book loss-of-exclusivity date.
• Paragraph IV risk is less important than regulatory, trademark, formulation, and manufacturing disputes.
• Chlorhexidine and alcohol-based antiseptics are the principal competitive threats.
• Financial upside depends on specialty mix, emerging-market expansion, and supply-chain control rather than ordinary antiseptic volume alone.

FAQs

Is povidone-iodine an excipient or an active pharmaceutical ingredient?

Povidone-iodine is generally regulated and labeled as an antiseptic active ingredient. Povidone alone is a pharmaceutical excipient used as a binder, solubilizer, film former, and stabilizer.

Does povidone-iodine have a DMF or USP-NF excipient profile?

Pharmaceutical-grade povidone may be supported by compendial specifications and manufacturer regulatory documentation. Povidone-iodine finished products require separate controls for iodine content, complex formation, stability, and microbiological quality.

Can chlorhexidine replace povidone-iodine in hospital products?

Not automatically. Substitution depends on indication, concentration, formulation, patient population, labeling, compatibility, and local regulatory requirements.

Are povidone-iodine products eligible for biosimilar competition?

No. Povidone-iodine is a small-molecule antiseptic complex, not a biologic. Biosimilar pathways do not apply.

Which povidone-iodine products have the best commercial prospects?

Specialty ophthalmic products, advanced wound-care systems, unit-dose applicators, controlled-release dressings, and formulations with documented tolerability have stronger commercial prospects than standard bulk solutions.

References

1. U.S. Food and Drug Administration. (2023). Drug products marketed for over-the-counter topical antiseptic use: Regulatory and monograph materials. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. European Medicines Agency. (2007). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMA.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

5. World Health Organization. (2019). WHO global guidelines for the prevention of surgical site infection. World Health Organization.